Nordea Investment Management AB Grows Stock Position in Charles River Laboratories International, Inc. $CRL

Key Points

• Nordea Investment Management AB boosted its stake in Charles River Laboratories (NYSE:CRL) by 43.6% in Q4, adding 16,616 shares to hold 54,694 shares worth about $10.99 million (≈0.11% of the company).
• Charles River has an $8.16 billion market cap, reported quarterly EPS of $2.39 (beating the $2.33 consensus) on $994.23M revenue, and set FY2026 guidance of 10.700–11.200 EPS.
• Analysts have a consensus rating of Moderate Buy with a $206.15 average price target, and institutional ownership is very high at 98.91%, with major holders like Vanguard, Ariel, Invesco and BofA recently adjusting positions.

Nordea Investment Management AB increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 43.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 54,694 shares of the medical research company's stock after buying an additional 16,616 shares during the quarter. Nordea Investment Management AB owned about 0.11% of Charles River Laboratories International worth $10,985,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of CRL. Vanguard Group Inc. lifted its holdings in shares of Charles River Laboratories International by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 5,839,743 shares of the medical research company's stock worth $913,686,000 after acquiring an additional 27,989 shares during the last quarter. Ariel Investments LLC grew its holdings in Charles River Laboratories International by 28.6% during the 2nd quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company's stock valued at $214,751,000 after purchasing an additional 314,572 shares during the last quarter. Invesco Ltd. grew its holdings in Charles River Laboratories International by 1.0% during the 3rd quarter. Invesco Ltd. now owns 1,249,178 shares of the medical research company's stock valued at $195,446,000 after purchasing an additional 12,035 shares during the last quarter. Bank of America Corp DE raised its position in Charles River Laboratories International by 13.4% in the 3rd quarter. Bank of America Corp DE now owns 1,163,348 shares of the medical research company's stock worth $182,017,000 after purchasing an additional 137,335 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Charles River Laboratories International by 11.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,130,905 shares of the medical research company's stock worth $176,909,000 after purchasing an additional 120,207 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Price Performance

Shares of CRL stock opened at $165.70 on Thursday. The company has a market capitalization of $8.16 billion, a P/E ratio of -55.98, a P/E/G ratio of 2.72 and a beta of 1.64. The company's 50-day simple moving average is $181.98 and its two-hundred day simple moving average is $180.65. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $228.88. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The firm had revenue of $994.23 million during the quarter, compared to the consensus estimate of $986.98 million. During the same quarter in the previous year, the firm posted $2.66 earnings per share. The company's revenue was down .8% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on CRL. UBS Group boosted their target price on Charles River Laboratories International from $170.00 to $175.00 and gave the company a "neutral" rating in a research report on Wednesday, February 25th. JPMorgan Chase & Co. increased their price target on Charles River Laboratories International from $165.00 to $190.00 and gave the stock a "neutral" rating in a report on Monday, December 15th. Bank of America upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and set a $225.00 price objective for the company in a report on Monday, December 15th. Robert W. Baird set a $193.00 price objective on Charles River Laboratories International in a research report on Thursday, February 19th. Finally, TD Cowen reduced their target price on Charles River Laboratories International from $251.00 to $235.00 and set a "buy" rating on the stock in a research note on Friday, February 20th. Ten equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of "Moderate Buy" and a consensus price target of $206.15.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.